Update shared on 10 Nov 2025
Fair value Increased 0.22%Analysts have modestly increased their price target for JD Health International, raising it from ¥70.10 to ¥70.25. They cite incremental improvements in projected revenue growth and profit margins as the reason for this adjustment.
What's in the News
- Mr. Enlin Jin has resigned as chief executive officer of JD Health International, effective September 29, 2025, to spend more time with his family (Key Developments).
- The Board has appointed Mr. Dong Cao as the new chief executive officer, effective September 29, 2025 (Key Developments).
- Mr. Dong Cao previously held roles within JD Group and was CFO of JD Health International from April 2019 to May 2023 (Key Developments).
- Prior to joining JD Group, Mr. Dong Cao held senior auditing and finance positions at other major companies. He is a certified public accountant (Key Developments).
Valuation Changes
- The Fair Value Estimate has risen slightly from HK$70.10 to HK$70.25.
- The Discount Rate has increased from 6.89% to 7.02%.
- The Revenue Growth projection has improved modestly from 14.90% to 15.01%.
- The Net Profit Margin forecast is essentially unchanged, moving from 7.06% to 7.06%.
- The Future P/E ratio has increased marginally from 36.01x to 36.15x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.